Japan Bio Science Laboratory (JBSL), Walnut Creek, CA, a manufacturer and supplier of nattokinase, has been awarded NSF Certification for NSK-SD. The industry’s only nattokinase ingredient fermented from the original Bacillus subtilis natto strain, NSK-SD has demonstrated the ability in numerous clinical studies to help dissolve excess fibrin, reduce blood platelet aggregation, decrease blood pressure and improve circulation.
 
“Earning NSF Certification for NSK-SD is a direct example of JBSL’s dedication to providing our industry with the premium nattokinase, backed by more than 35 studies,” said Vincent Hackel, president of JBSL-USA, Incorporated. “This certification provides additional validation for our NSK-SD ingredient, and we will continue to rely on the science behind NSK-SD to provide differentiation in the marketplace. NSK-SD is the only nattokinase, for example, whose thrombolytic activity (dissolving greater than 20,000 fibrinogen degradation units per gram) has been demonstrated in human studies.”
 
The registration by NSF International states JBSL is in compliance with Good Manufacturing Practices (GMP), as set forth in NSF International Certification Guideline 229, Functional Foods. These GMP are consistent with Food & Drug Administration (FDA) cGMP for food products (21 CFR 110.3).
 
Currently, JBSL has two Japanese patents and three U.S. patents for its technology in producing NSK-SD. Research has uncovered properties of NSK-SD that make it an attractive daily supplement to support healthy cardiovascular function. Specifically, studies have shown NSK-SD to promote arterial health via thrombolytic activity, reduce whole blood viscosity, promote normal blood pressure and normal clotting, inhibit platelet aggregation and increase healthy blood circulation.